Payment overview · 2025
General Payments
$1,260.76
64 reported records · 11 companies
Healthcare provider profile · identity verified
Chin Se Kim, M.D.
Allopathic & Osteopathic Physicians|Neuromusculoskeletal Medicine, Sports Medicine · ANAHEIM, CA · NPI 1477564607
Verified facts
What the public records show
CMS Open Payments records show Chin Se Kim, M.D. received $1,260.76 in general payments during 2025 across 64 reported records.
Amgen Inc. accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Prolia, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $546.79 | 43.4% | 36 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $155.34 | 12.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.31 | 11.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $120.15 | 9.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $115.56 | 9.2% | 4 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $66.12 | 5.2% | 3 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $29.42 | 2.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.00 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.65 | 1.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.08 | 1.5% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $16.34 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,260.76 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $420.33 | 24 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $180.81 | 22 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.31 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $126.46 | 12 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $120.15 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $115.56 | 4 | 2025 |
Source payment records
|
|||||
| XCELL Normalized: xcell |
Device | Bioventus LLC | $91.18 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $66.12 | 3 | 2025 |
Source payment records
|
|||||
| SUPARTZ FX SODIUM HYALURONATE Normalized: supartz fx sodium hyaluronate |
Device | Bioventus LLC | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $25.07 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 56 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
56 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1033 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 604 | 133 |
| Losartan Potassium | Losartan Potassium | 578 | 118 |
| Metformin Hcl | Metformin Hcl | 373 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 229 | 38 |
| Gabapentin | Gabapentin | 202 | 67 |
| Alendronate Sodium | Alendronate Sodium | 185 | 50 |
| Vascepa | Icosapent Ethyl | 185 | 24 |
| Donepezil Hcl | Donepezil Hcl | 179 | 28 |
| Omeprazole | Omeprazole | 166 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 32 |
| Januvia | Sitagliptin Phosphate | 152 | 24 |
| Ibuprofen | Ibuprofen | 142 | 69 |
| Azithromycin | Azithromycin | 138 | 99 |
| Memantine Hcl | Memantine Hcl | 128 | 23 |
| Creon | Lipase/Protease/Amylase | 121 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 111 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 97 | 48 |
| Simvastatin | Simvastatin | 96 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 89 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 22 |
| Celecoxib | Celecoxib | 85 | 20 |
| Famotidine | Famotidine | 83 | 19 |
| Sertraline Hcl | Sertraline Hcl | 78 | 12 |
| Ezetimibe | Ezetimibe | 77 | 20 |
| Finasteride | Finasteride | 76 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 15 |
| Farxiga | Dapagliflozin Propanediol | 73 | suppressed |
| Furosemide | Furosemide | 71 | 11 |
| Lisinopril | Lisinopril | 71 | 15 |
| Alprazolam | Alprazolam | 68 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 13 |
| Carvedilol | Carvedilol | 58 | suppressed |
| Jardiance | Empagliflozin | 57 | suppressed |
| Rybelsus | Semaglutide | 57 | suppressed |
| Prolia | Denosumab | 56 | 32 |
| Glipizide | Glipizide | 55 | 16 |
| Montelukast Sodium | Montelukast Sodium | 55 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 53 | 11 |
| Potassium Chloride | Potassium Chloride | 51 | suppressed |
| Meloxicam | Meloxicam | 50 | 14 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Eliquis | Apixaban | 48 | suppressed |
| Glimepiride | Glimepiride | 48 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 23 |
| Atenolol | Atenolol | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Temazepam | Temazepam | 40 | 20 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 39 | 11 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Lidocaine | Lidocaine | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 14 |
| Acyclovir | Acyclovir | 32 | 18 |
| Ketoconazole | Ketoconazole | 32 | suppressed |
| Restasis | Cyclosporine | 32 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Ciclopirox | Ciclopirox | 26 | 11 |
| Cyclosporine | Cyclosporine | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 26 | 12 |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Prednisone | Prednisone | 21 | 13 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Bicalutamide | Bicalutamide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,260.76 · 64 records | Amgen Inc. | CAPLYTA, Cologuard Collection Kit, DUROLANE, EVENITY, Fibroscan, JOURNAVX, Kerendia, MONOVISC, ORTHOVISC, OTEZLA, Ozempic, PROLIA, QUTENZA, REPATHA, SUPARTZ FX SODIUM HYALURONATE, XCELL, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error